Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA nanotechnology task force

This article was originally published in The Gray Sheet

Executive Summary

Newly formed task force will assess the agency's readiness to handle a swelling wave of medical nanotechnology, wherein the control of matter at the nano level - one thousand- to one hundred thousand-times smaller than the thickness of a sheet of paper - enables novel applications, according to an Aug. 9 release (1"The Gray Sheet" April 24, 2006, p. 12). The task force will seek to identify gaps in policy and/or institutional knowledge and craft regulatory approaches that encourage the continued development of devices that incorporate nanomaterials. A public meeting is scheduled for Oct. 10 to explore such topics as the biological interactions unique to nanotechnology that may lead to either beneficial or adverse health effects...

You may also be interested in...



FDA’s Preparedness For Nanotech Debated At Public Meeting

A former FDA deputy commissioner joined other speakers at an Oct. 10 meeting in urging the agency to seek additional expertise and resources in its oversight of products that rely on materials controllable at scales as small as one-billionth of a meter

FDA Inks Nanotech Agreement With Cancer And Standards Institutes

FDA collaboration in the nanotechnology field with two other federal agencies may serve to facilitate premarket reviews for nanotech-based cancer diagnostics and therapeutics

FDA Will Consider Nano-Ingredients At An October Meeting

Medical products manufactured using materials that can be measured and controlled at dimensions one thousand- to one hundred thousand-times smaller than the thickness of a sheet of paper will be the subject of a public meeting FDA is planning for mid-October

Related Content

UsernamePublicRestriction

Register

MT023873

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel